Quantification of amyloid PET for future clinical use: a state-of-the-art review

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Pemberton, Hugh G.
• dc.contributor.author Collij, Lyduine E.
• dc.contributor.author Heeman, Fiona
• dc.contributor.author Bollack, Ariane
• dc.contributor.author Shekari, Mahnaz
• dc.contributor.author Salvadó, Gemma
• dc.contributor.author Lopes Alves, Isadora
• dc.contributor.author Vallez Garcia, David
• dc.contributor.author Battle, Mark
• dc.contributor.author Buckley, Christopher, 1948-
• dc.contributor.author Stephens, Andrew W.
• dc.contributor.author Bullich, Santiago
• dc.contributor.author Garibotto, Valentina
• dc.contributor.author Barkhof, Frederik
• dc.contributor.author Gispert López, Juan Domingo
• dc.contributor.author Farrar, Gill
• dc.contributor.author AMYPAD Consortium
• dc.date.accessioned 2022-09-16T06:22:37Z
• dc.date.available 2022-09-16T06:22:37Z
• dc.date.issued 2022
• dc.description.abstract Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be determined in vivo using positron emission tomography (PET), for which three fluorine-18 labelled radiotracers have been approved for clinical use. In clinical practice, trained readers will categorise scans as either Aβ positive or negative, based on visual inspection. Diagnostic decisions are often based on these reads and patient selection for clinical trials is increasingly guided by amyloid status. However, tracer deposition in the grey matter as a function of amyloid load is an inherently continuous process, which is not sufficiently appreciated through binary cut-offs alone. State-of-the-art methods for amyloid PET quantification can generate tracer-independent measures of Aβ burden. Recent research has shown the ability of these quantitative measures to highlight pathological changes at the earliest stages of the AD continuum and generate more sensitive thresholds, as well as improving diagnostic confidence around established binary cut-offs. With the recent FDA approval of aducanumab and more candidate drugs on the horizon, early identification of amyloid burden using quantitative measures is critical for enrolling appropriate subjects to help establish the optimal window for therapeutic intervention and secondary prevention. In addition, quantitative amyloid measurements are used for treatment response monitoring in clinical trials. In clinical settings, large multi-centre studies have shown that amyloid PET results change both diagnosis and patient management and that quantification can accurately predict rates of cognitive decline. Whether these changes in management reflect an improvement in clinical outcomes is yet to be determined and further validation work is required to establish the utility of quantification for supporting treatment endpoint decisions. In this state-of-the-art review, several tools and measures available for amyloid PET quantification are summarised and discussed. Use of these methods is growing both clinically and in the research domain. Concurrently, there is a duty of care to the wider dementia community to increase visibility and understanding of these methods.
• dc.format.mimetype application/pdf
• dc.identifier.citation Pemberton HG, Collij LE, Heeman F, Bollack A, Shekari M, Salvadó G, Alves IL, Garcia DV, Battle M, Buckley C, Stephens AW, Bullich S, Garibotto V, Barkhof F, Gispert JD, Farrar G; AMYPAD consortium. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging. 2022 Aug;49(10):3508-28. DOI: 10.1007/s00259-022-05784-y
• dc.identifier.doi http://dx.doi.org/10.1007/s00259-022-05784-y
• dc.identifier.issn 1619-7070
• dc.identifier.uri http://hdl.handle.net/10230/54088
• dc.language.iso eng
• dc.publisher Springer
• dc.relation.ispartof Eur J Nucl Med Mol Imaging. 2022 Aug;49(10):3508-28
• dc.rights © The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Alzheimer’s
• dc.subject.keyword Amyloid
• dc.subject.keyword Brain
• dc.subject.keyword Centiloid
• dc.subject.keyword Dementia
• dc.subject.keyword PET
• dc.subject.keyword Quantification
• dc.subject.keyword SUVr
• dc.title Quantification of amyloid PET for future clinical use: a state-of-the-art review
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion